Laboratory findings challenge the idea of metabolic neutrality.
Cambridge | July 2026
Low-calorie sweeteners may interact directly with intestinal bacteria, and their effects can change substantially when they are consumed alongside common medications or food additives, according to new laboratory research from the University of Cambridge.
The findings challenge the widespread assumption that artificial and low-calorie sweeteners simply pass through the body without influencing its internal microbial ecosystem. They also introduce a more complex question: the biological effect of a sweetener may depend not only on the substance itself, but also on what a person eats, drinks or takes as medication at the same time.
Researchers from the Medical Research Council Toxicology Unit examined 39 commercially used sweeteners and sugar substitutes against 25 bacterial strains selected to represent the diversity of microorganisms found in a healthy human intestine. The group included commensal bacteria, probiotic species and opportunistic organisms.
The scientists tested 975 individual sweetener-bacteria pairings under controlled laboratory conditions. Approximately three-quarters of the sweeteners altered the growth of at least one bacterial strain, although the direction and intensity of the response differed considerably between compounds and species.
Some sweeteners suppressed bacterial growth, while others promoted it. Isosteviol, a compound related to the metabolism of steviol glycosides, produced some of the strongest individual effects. It inhibited several bacterial species while stimulating the growth of another.
The result does not mean that every sweetener destroys the microbiota or that all bacterial changes are necessarily harmful. The intestinal ecosystem contains hundreds of species that communicate, compete and exchange metabolic products. An increase or decrease in one organism cannot be interpreted automatically as a clinical benefit or danger.
The study’s most significant contribution emerged when the researchers examined mixtures rather than isolated compounds. Sweeteners are rarely consumed alone. They appear in coffee, soft drinks, desserts, chewing gum, cereals, snacks and medicines, where they coexist with caffeine, flavourings, pharmaceutical ingredients and other additives.
The team therefore combined the sweeteners with advantame, caffeine, vanillin and the antidepressant duloxetine. It also tested selected sweeteners with eight commonly used medications, including acetaminophen, ibuprofen, cetirizine, montelukast, risperidone and aripiprazole.
Across thousands of experimental combinations, the researchers identified 102 significant interactions involving nine bacterial species. Thirty-four were synergistic, meaning the combined effect was stronger than expected from the two substances acting separately. Another 68 were antagonistic, with one compound reducing or modifying the effect of the other.
The strongest synergy involved isosteviol and duloxetine. Together, the compounds markedly inhibited Roseburia intestinalis, a bacterium associated with glucose regulation and protection against intestinal inflammation.
The same combination also reduced the presence of Parabacteroides merdae, a common member of the healthy microbiota. When the researchers introduced both substances into a synthetic community formed from the 25 bacterial strains, overall microbial diversity declined more than it did with either compound alone.
The combination affected several additional bacteria and altered the metabolism of the experimental community. Material secreted by the treated bacteria increased toxicity toward one laboratory cell line and modified the release of the inflammation-related signalling molecules IL-6 and IL-8 in intestinal cells.
These observations suggest that sweeteners and medications could influence not only which bacteria survive, but also the molecules those microorganisms produce and the way nearby human cells respond.
The results remain preliminary from a medical perspective. The experiments were conducted entirely in vitro, using individual bacterial cultures, synthetic communities and laboratory cell lines. They did not involve patients consuming sweeteners and duloxetine under normal dietary conditions.
A laboratory concentration does not necessarily reproduce the amount reaching the human colon after digestion, absorption and metabolism. The actual intestine is also considerably more complex than an experimental culture, containing hundreds of microbial species, immune cells, food residues and chemical conditions that vary continuously between individuals.
The research therefore does not establish that consuming a sweetener while taking duloxetine causes intestinal disease, inflammation or metabolic dysfunction. It also provides no basis for discontinuing prescribed medication without medical guidance.
Duloxetine is used to treat depression, anxiety disorders, certain forms of chronic pain and diabetic peripheral neuropathy. Abruptly stopping it can produce withdrawal symptoms and destabilize the condition for which it was prescribed.
The findings instead identify combinations that deserve further investigation in animals and humans. Future clinical studies would need to determine whether the interactions occur at realistic dietary concentrations, how long any microbial changes persist and whether they produce measurable consequences for glucose control, immunity or gastrointestinal health.
Individual variation will be another decisive factor. Two people can consume the same product and experience different microbiome responses because their bacterial communities, diets, medication histories and metabolic conditions are not identical.
The research also raises questions for food and pharmaceutical manufacturers. Sweeteners are frequently included in tablets, syrups and dissolvable medicines to mask bitterness. Product safety assessments traditionally evaluate individual ingredients, but may not fully capture the biological consequences of combinations encountered during everyday consumption.
For consumers, the most responsible interpretation is moderation rather than alarm. Approved sweeteners remain regulated for use within established intake limits, and replacing large quantities of added sugar can still be useful in specific nutritional or medical contexts.
However, “low calorie” should not be interpreted as biologically inactive. The intestinal microbiota may detect and respond to substances that contribute little or no energy to the human body.
The study does not deliver a final verdict on sweeteners. It reveals that their effects may depend on the chemical company they keep.
Phoenix24 | Health knowledge for informed decisions. Conocimiento en salud para decisiones informadas.